A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

Journal of Chemotherapy

Volumn 13, Issue 2, 2001, Pages 202-205

  Tognoni, A ^a   Pensa, F ^a   Vaira, F ^a   Vigani, A ^a   Bancalari, L ^a   Fiasella, L ^a   Maggiani, R ^a   Canessa, P ^a   Pronzato, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cisplatin; Gemcitabine; Ifosfamide; Non small cell lung cancer; Toxicity in cancer therapy

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; TREATMENT OUTCOME;

EID: 0035057693     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.2.202     Document Type: Article

References (17)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Single agent gemcitabine versus cisplatin-etoposide: Early results of a a randomized phase II study in locally advanced or metastatic non-small cell lung cancer
3. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer
4. Chemotherapy of advanced non-small cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
5. High dose intensity chemotherapy with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor in the treatment of small cell lung cancer
6. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung. A randomized trial investigating two dosages schedules
7. Cisplatin plus etoposide at maximum tolerated dose with or without recombinant human granulocyte-macrophage colony-stimulating factor in advanced non-small cell lung cancer. A phase III randomized trial
8. Combination chemotherapy versus carboplatin or iproplatin followed by combination chemotherapy in stage IV non-small cell lung cancer
9. The influence of the addition of mitomycin to vindesine plus cisplatin in a random assignment trial in 120 patients with non-small cell lung cancer
10. Chemotherapy of advanced non-small cell lung cancer. A randomized trial of three cisplatin based chemotherapy regimens
11. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of European multicenter trial including 612 patients
12. A phase II study of a three-drug combination (cisplatin, ifosfamdie and vinorelbine) plus granulocyte-colony stimulating factor in advanced non-small-cell lung cancer
13. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
14. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of stage IIIB-IV non-small cell lung cancer (NSCLC). A phase II study of the Italian Oncology Group for Clinical Research
15. Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC)
16. Phase II activity of cisplatin (CDDP) plus ifosfamide (IFO) and gemcitabine (GEM) in non-small cell lung cancer (NSCLC): Preliminary results
17. Gemcitabine, ifosfamide, cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial